Ironwood Pharmaceuticals Provides Second Quarter 2016 Investor Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Ironwood Pharmaceuticals Provides Second Quarter 2016 Investor Update
August 5, 2016 9:03 AM EDT
Leerink Partners reiterated a Market Perform rating on Ironwood Pharmaceuticals (NASDAQ: IRWD), and raised the price target to $14.00 (from $10.00), following the company's 2Q earnings report. Linzess sales grew to $150.5m, ~2% above forecasts. Underlying sales growth of +34% was driven by 29% Rx volume growth. IRWD will launch Zurampic (gout) in October 2016. Zurampic... More
August 4, 2016 4:19 PM EDT
Ironwood Pharma (NASDAQ: IRWD) reported Q2 EPS of ($0.16), $0.01 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $54.4 million versus the consensus estimate of $55.46 million.
For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.
...
More
